Physician profile
Lan Quang
NPI 1437354347
$16,908.07
in general payments reported to CMS, 2019-2025
47 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $1,577 · 2021: $2,373 · 2022: $2,835 · 2023: $2,843 · 2024: $3,425 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,391 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,390.89 |
| Education | $138.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,994.15 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,732.28 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $1,326.44 | 2019-2025 | Veltassa |
| Novo Nordisk INC | $1,136.18 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $1,001.61 | 2020-2025 | Jynarque, Rexulti, Voyxact |
| Lilly USA, LLC | $949.38 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $810.38 | 2019-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $777.35 | 2021-2025 | Velphoro, Velphoro |
| Janssen Pharmaceuticals, INC | $631.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $616.53 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $583.60 | 2021-2025 | |
| Horizon Therapeutics Plc | $575.17 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $550.59 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $494.86 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $492.55 | 2022-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Quang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.